Displaying drugs 426 - 450 of 8039 in total
Captopril
Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Approved
Matched Description: … Captopril may be used in the treatment of hypertension. ... for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ... Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible …
Macitentan
Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It was first approved by the FDA in 2013. Macitentan differs from its predecessor bosentan in part due to its lower risk of hepatotoxicity.
A combination product (Opsynvi) comprising macitentan and tadalafil was approved...
Approved
Matched Description: … Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension ... Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity. ... Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of …
Vonoprazan
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. Furthermore, vonoprazan is 350-times more potent...
Approved
Investigational
Matched Description: … to an _H. pylori_ eradication rate of approximately 90%. ... and clarithromycin for the treatment of _H. pylori_ infection. ... PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. …
Edaravone
Edaravone is a free radical scavenger and neuroprotective agent with antioxidant properties. It has three tautomers. Edaravone works to scavenge reactive oxygen species, which have been implicated in neurological disorders, such as amyotrophic lateral sclerosis (ALS) and cerebral ischemia.[A19140,L44007,A254257]
The intravenous formulation of edaravone was first approved in Japan in...
Approved
Investigational
Matched Description: … for the treatment of acute ischemic stroke. ... [L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and ... [A19140,L44007,A254257]
The intravenous formulation of edaravone was first approved in Japan in 2001 …
Candesartan cilexetil
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone...
Approved
Matched Description: … the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of ... It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, ... Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough …
Glycyrrhizic acid
Glycyrrhizic acid is extracted from the root of the licorice plant; Glycyrrhiza glabra. It is a triterpene glycoside with glycyrrhetinic acid that possesses a wide range of pharmacological and biological activities. When extracted from the plant, it can be obtained in the form of ammonium glycyrrhizin and mono-ammonium glycyrrhizin. Glycyrrhizic...
Approved
Experimental
Matched Description: … Glycyrrhizic acid is extracted from the root of the licorice plant; _Glycyrrhiza glabra_. ... [F79] It is a triterpene glycoside with glycyrrhetinic acid that possesses a wide range of pharmacological ... [T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of …
Patisiran
Parisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis . It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. The approval for Onpattro...
Approved
Investigational
Matched Description: … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. ... Parisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy …
Acalabrutinib
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic...
Approved
Investigational
Matched Description: … of this drug with proton pump inhibitors (PPIs). ... have an effect in the pharmacokinetics of acalabrutinib. ... To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian …
Trihexyphenidyl
Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant...
Approved
Matched Description: … Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced ... [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment …
Fluticasone propionate
Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990 .
Approved
Oxaprozin
Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Approved
Ticagrelor
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y12 receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU, .
Ticagrelor was...
Approved
Vismodegib
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib...
Approved
Investigational
Matched Description: … [A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule ... The Hedgehog signaling pathway plays an important role in the development of organs and tissues during ... [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal …
Aliskiren
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in...
Approved
Investigational
Matched Description: … Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension …
Trilaciclib
Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis...
Approved
Investigational
Matched Description: … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy …
Spiramycin
Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.
Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in...
Approved
Matched Description: … Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens ... Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of …
Vedolizumab
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 interaction, leading to the mobilization...
Approved
Matched Description: … humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of ... and gut endothelial cells through the α4β7 integrin-MAdCAM1 interaction, leading to the mobilization of ... migration into the intestinal tract included α2β2, α4β1, and α4β7; however, the selective activity of …
Sacubitril
Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the FDA after being given the status of priority review for on July 7, 2015....
Approved
Matched Description: … Inhibition of neprilysin therefore leads to reduced breakdown and increased concentration of endogenous ... Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of ... It was approved by the FDA after being given the status of priority review for on July 7, 2015. …
Benralizumab
Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R,...
Approved
Investigational
Matched Description: … [A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta ... subunits of the IL-5R, thus blocking signal transduction. ... Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that …
Enfuvirtide
Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting...
Approved
Investigational
Matched Description: … biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of ... The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide …
Timolol
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers...
Approved
Matched Description: … This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of …
Oxaliplatin
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride...
Approved
Investigational
Matched Description: … [A260396] However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair ... [A260396] Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through ... [A797] However, this leads to poorer water solubility, which was compensated by the addition of the chloride …
Mycophenolic acid
Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties. . Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus)...
Approved
Investigational
Matched Description: … [A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its ... [A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an ... Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin …
Topotecan
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Approved
Investigational
Displaying drugs 426 - 450 of 8039 in total